

Novel treatment strategies for upper tract urothelial cancer

Learning program includes four independent activities

Expert perspective presentation:

In my clinic: novel developments and best practices for UTUC

While radical nephroureterectomy remains the gold standard for managing upper-tract urothelial cancer (UTUC), it is associated with major complications and loss of renal function. Nephron-sparing modalities are less invasive and offer an alternative approach for managing low-risk, low-grade UTUC. In this video presentation, Dr Gary Steinberg addresses unmet needs in the management of UTUC and provides insights into choosing kidney-sparing approaches. New developments involving chemoablation for low-grade UTUC, and how these fit into the current treatment algorithm, are also discussed.

Faculty

Gary D. Steinberg, MD, Professor and Director Goldstein Urology Bladder Cancer Program, NYU Langone Health Perlmutter Cancer Center, New York, NY, USA

Release date: September 30, 2020

Expiration date: September 30, 2021

Estimated time to completion: 0.5 hour

Roundtable discussion webcast:

Expert insights on novel treatment options for UTUC

What is the latest evidence-based thinking on the management of upper-tract urothelial cancer (UTUC)? In this lively roundtable discussion, three leading experts review and discuss key practical issues. They provide insights into current challenges in UTUC management, along with updates on staging, grading, and risk stratification for identification of patients who are candidates for kidney-sparing approaches. The experts also discuss recent clinical efficacy and safety data on chemoablation for low-grade UTUC and the risk/benefit profile in relation to traditional surgical treatments, offering a rationale for the use of each of these approaches in candidate patients.

Faculty

Dr Seth Paul Lerner, MD, Professor of Urology, Director of Urologic Oncology and the Multidisciplinary Bladder Cancer Program, and Vice-Chair for Faculty Affairs, Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA

Dr Surena Matin, MD, Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Dr Phillip Pierorazio, MD, Associate Professor of Urology and Oncology, Brady Urological Institute at Johns Hopkins University, Baltimore, MD, USA

Release date: November, 2020

Expiration date: November, 2021

Estimated time to completion: 0.5 hour

Available CME Credits: AMA, ANCC and ACPE credits will be available

Interactive patient case:

Appropriate treatment selection in low-grade UTUC

The interactive case, based on a patient in the real world, allows participants to follow a patient from assessment through to treatment, providing practical guidance along the way on staging, grading, and risk stratification. The case highlights the factors that influence the choice of therapy for patients with low-grade upper-tract urothelial cancer (UTUC) and provides practical recommendations for implementing newly available kidney-sparing approaches, such as chemoablation, in the clinic.

Faculty

Dr Seth Paul Lerner, MD, Professor of Urology, Director of Urologic Oncology and the Multidisciplinary Bladder Cancer Program, and Vice-Chair for Faculty Affairs, Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA

Release date: December, 2020

Expiration date: December, 2021

Estimated time to completion: 0.5 hour

Available CME Credits: AMA, ANCC and ACPE credits will be available

**Interactive infographic:
Practical guidance on UTUC patient stratification**

The infographic allows participants to review best practices in risk stratification in upper-tract urothelial cancer (UTUC) and in selecting patients for appropriate treatment, including new kidney-sparing approaches.

Faculty

Dr Phillip Pierorazio, MD, Associate Professor of Urology and Oncology, Brady Urological Institute at Johns Hopkins University, Baltimore, MD, USA

Release date: February, 2021

Expiration date: February, 2022

Estimated time to completion: 0.5 hour

Joint accreditation statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Ology Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

Method of participation and request for credit

There are no fees for participating in, and receiving CME/CE credit for, any activity.

In order to claim credit, participants must complete the following procedures during the period September 30, 2020 through December 31, 2021.

1. Choose a learning activity
2. Read the educational objectives, accreditation information, and faculty disclosures
3. Take the pre-activity test
4. View the webcast or complete the patient case activity
5. Take the post-activity test and complete the evaluation
6. Download the certificate of CME credit or certificate of attendance

Disclosure of conflicts of interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty	Relationship identified with:
Dr Gary D Steinberg	Consulting fees for Cold Genesys, Heat Biologics, FKD, Taris Biomedical, PhotoCure, Roche/Genentech, Fidia Farm., Astra/Zeneca, Ciclomed, Boston Scientific, Merck, Ferring, FerGene, Urogen, Epivax Oncology, MDxHealth, Natera, Janssen, Aduro Biotech, SesenBio, Asieris, EnGene Bio, BMS, Pfizer, Nucleix, Dendreon, Seattle Genetics, AbbVie and equity/stock options in Epivax Oncology, Urogen
Dr Seth P Lerner	Receipt of Intellectual Property Rights for The Broad Institute and BCAN, Consulting Fees from FerGene, Genentech (SWOG), Merck, Pfizer, QED, UroGen, Vaxiion and Verity, Fees for Non-CME/CE Services Received Directly from a Commercial Interest from UroToday and Grand Rounds in Urology, Contracted Research for Endo, Viventia, Vaxiion, UroGen and FKD
Dr Philip Pierorazio	Consulting fees from UroGen Pharmaceuticals, Contracted Research from OLYMPUS trial, Site Principal Investigator (Urogen Pharma)
Dr Surena F Matin	Consulting Fees from QED Therapeutics, Taris Bio

Planners and managers

The PIM planners and managers have nothing to disclose. The Ology Medical Education planners and managers have nothing to disclose.

Provider information

Jointly provided by Postgraduate Institute for Medicine and Ology Medical Education.

Financial support

This activity is supported by an independent educational grant from UroGen Pharma Inc.

Disclosure of unlabeled use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. The course materials are for educational purposes only and should not be reproduced or distributed in any way. If you wish to reproduce, store in a retrieval system, transmit in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, any part of the material presented, you will need to obtain all the necessary permissions by writing to the publisher, the original author, or any other current copyright owner.

Contact information for questions about the activity

info@ologyeducation.org, www.ologyeducation.org
inquiries@pimed.com, www.pimed.com

System requirements

Ology Education requires a modern web browser (Google Chrome, Mozilla Firefox, Apple Safari, Microsoft Edge). Certain educational activities may require a PDF reader such as Adobe Acrobat Reader to view.

Media

Internet